Browsing Tag
AP02
2 posts
Why is Avalyn Pharma going public now, and what does it reveal about biotech risk appetite?
Avalyn Pharma has filed for a U.S. IPO to fund inhaled pulmonary fibrosis drugs. Read what the move signals for biotech markets and lung disease therapy.
Can inhaled nintedanib improve tolerability and adherence in IPF treatment, according to Avalyn Pharma Inc.?
Avalyn Pharma advances AP02 into Phase 2 trials, testing inhaled drug delivery as a safer IPF strategy. Discover what this means for the fibrosis market.